Today: 23 January 2026
Subscribe
Browse Category

NYSE:BSX News 15 January 2026 - 20 January 2026

Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares

Boston Scientific stock rises as BSX teases new pain-therapy data while FDA stent alert hangs over shares

New York, January 20, 2026, 14:21 EST — Regular session ongoing. Shares of Boston Scientific Corp climbed roughly 3.1% to $90.77 on Tuesday, clawing back some of last week’s losses. Investors digested new clinical data amid ongoing concerns over regulatory issues and deal rumors. This shift is significant since BSX is back to being a “show me” stock. Traders are…
20 January 2026
···
Boston Scientific stock price slides again as $14.5B Penumbra deal puts debt, dilution in focus

Boston Scientific stock price slides again as $14.5B Penumbra deal puts debt, dilution in focus

New York, Jan 16, 2026, 20:00 ET — Market closed. Boston Scientific Corporation (BSX) shares dropped 2.18% on Friday, closing at $88.07. It marked their seventh consecutive day of declines, with volume heavier than usual. The S&P 500 slipped 0.06%, the Dow fell 0.17%, and competitors Abbott and Medtronic also finished in the red. (MarketWatch) Shares slid after Boston Scientific…
17 January 2026
····
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

New York, January 16, 2026, 2:57 PM EST — Regular session Shares of Boston Scientific Corp dropped 1.8% to $88.44 Friday afternoon, deepening losses following its deal to acquire clot-removal specialist Penumbra. Meanwhile, Penumbra’s stock ticked up 0.3%, reaching $351.62. Boston agreed Thursday to acquire Penumbra for $14.5 billion, combining cash and stock in a deal Reuters flagged as its…
16 January 2026
····
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

New York, Jan 15, 2026, 18:09 (ET) — After-hours update. Shares of Boston Scientific Corp (NYSE: BSX) dropped roughly 4% Thursday following its deal to acquire blood-clot treatment company Penumbra. Boston Scientific’s stock slipped $3.75, closing near $90.03 in late U.S. trading. Meanwhile, Penumbra (NYSE: PEN) surged around 12%, reaching $350.49. Boston Scientific announced it will pay $374 per Penumbra…
16 January 2026
·····
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

New York, Jan 15, 2026, 16:52 (EST) — After-hours Penumbra, Inc. shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced plans to acquire the clot-removal device maker in a roughly $14.5 billion deal. The stock reached an after-hours high of $369.84 but remained about $23 short of the $374 offer price, reflecting lingering merger risk and…
15 January 2026
····
Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS

Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS

New York, January 15, 2026, 11:05 EST Boston Scientific (BSX) struck a deal to acquire Penumbra (PEN) for roughly $14.5 billion on Thursday, drawing attention to the medical device sector. This move came amid Verizon’s (VZ) ongoing outage issues and new earnings reports from Goldman Sachs (GS) and Morgan Stanley (MS). The Penumbra deal marks the first significant healthcare takeover…
15 January 2026
····
Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston, Jan 15, 2026, 08:19 (EST) Boston Scientific announced Thursday it will acquire medical device maker Penumbra for roughly $14.5 billion in a cash-and-stock transaction, valuing Penumbra at $374 per share. Penumbra’s shares jumped over 13% in premarket trading. The offer comes at a 19.3% premium to Penumbra’s previous close, Reuters reported. (Reuters) The deal is significant as it drives…
15 January 2026
····

Stock Market Today

  • Apple Stock Outlook: Growth, AI Adoption, and Market Position
    January 23, 2026, 12:18 PM EST. Apple (AAPL) has delivered remarkable long-term returns, with shares soaring over 900% in the past decade. The company's strong product lineup, particularly the iPhone, helped it claim the top spot in the 2025 smartphone market with a 20% share. Despite recent underperformance versus the S&P 500 due to slow initial AI adoption and tariff concerns tied to its China supply chain, Apple is accelerating its AI integration and benefiting from U.S. tariff exemptions related to domestic production investments. Growth in shipments and improved return on invested capital point to effective investment strategies. Investors eyeing potential catalysts this year may find Apple's evolving AI efforts and stabilizing trade environment a solid basis for future gains.
Go toTop